Compare TXG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | SYRE |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.5B |
| IPO Year | 2019 | 2015 |
| Metric | TXG | SYRE |
|---|---|---|
| Price | $69.75 | $90.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $20.25 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | N/A |
| 52 Week Low | $11.17 | $14.51 |
| 52 Week High | $69.67 | $110.18 |
| Indicator | TXG | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 42.01 |
| Support Level | $58.70 | $82.83 |
| Resistance Level | N/A | $105.09 |
| Average True Range (ATR) | 3.35 | 4.08 |
| MACD | -0.10 | -0.58 |
| Stochastic Oscillator | 79.58 | 22.81 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.